Ramalingam, Suresh S <br/><br/>
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.  [electronic resource] 

 -  Clinical lung cancer  05 2018 
 - 270-279.e3 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1938-0690 
<br/><br/><label>Standard No.: </label>10.1016/j.cllc.2017.12.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Age Factors<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Docetaxel--administration & dosage<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Salvage Therapy--methods<br/>Vascular Endothelial Growth Factor Receptor-2--antagonists & inhibitors<br/>Young Adult<br/>Ramucirumab